| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-03-04 | Warp Drive Bio (USA - MA) | nomination |
Cancer - Oncology - Infectious diseases | Nomination | ||
| 2015-03-03 | Islet Sciences (USA - NC) Brighthaven Ventures (USA - NC) | remogliflozin etabonate | NASH (non-alcoholic steatohepatitis) | licensing development commercialisation |
Hepatic diseases - Liver diseases - Metabolic diseases | Licensing agreement |
| 2015-03-03 | Actavis (Ireland) AstraZeneca (UK) | Actavis’ branded respiratory portfolio in the US and Canada | pipeline acquisition |
Respiratory diseases - Inflammatory diseases - Allergic diseases | Pipeline acquisition | |
| 2015-03-03 | Fate Therapeutics (USA - CA) | nomination |
Cancer - Oncology - Rare diseases - Genetic diseases - Hematological diseases | Nomination | ||
| 2015-03-03 | OncoDNA (Belgium) Biosequence (Spain) | OncoDEEP DX, Package PLUS and Clinical cancer panels | distribution |
Cancer - Oncology | Distribution agreement | |
| 2015-03-03 | Acacia Pharma (UK) | nomination |
Nomination | |||
| 2015-03-03 | Atara Biotherapeutics (USA - CA) | nomination |
Cancer - Oncology - Kidney diseases - Renal diseases | Nomination | ||
| 2015-03-02 | Chugai Pharmaceutical (Japan) Athersys (USA - OH) | MultiStem® | ischemic stroke | licensing commercialisation |
Cerebrovascular diseases | Licensing agreement |
| 2015-03-02 | G&W Laboratories (USA - NJ) Teva Pharmaceutical Industries (Israel) | Sellersville, Pennsylvania facility | plant acquisition |
Plant acquisition | ||
| 2015-03-02 | Ipsen (France) | nomination |
Cancer - Oncology - Endocrinological diseases | Nomination | ||
| 2015-03-02 | Macrocure (Israel) | nomination |
Nomination | |||
| 2015-03-02 | Incyte (USA - DE) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
| 2015-02-27 | Clinigen (UK) Merck&Co (USA - NJ) | human health products for use in clinical trials | distribution |
Distribution agreement | ||
| 2015-02-27 | Macrophage Therapeutics (USA - OH) | nomination |
Cancer - Oncology - Immunological diseases - Autoimmune diseases - Cardiovascular diseases | Nomination | ||
| 2015-02-27 | Kite Pharma (USA - CA) National Cancer Institute (USA) | T cell receptor (TCR) and chimeric antigen receptor (CAR) product candidates | solid tumors | collaboration R&D |
Cancer - Oncology | Collaboration agreement |
| 2015-02-26 | Triphase Accelerator (Canada - USA - CA) Sunnybrook Research Institute (Canada) | TRPH 011 | R&D |
Cancer - Oncology | R&D agreement | |
| 2015-02-25 | AstraZeneca (UK) Orca Pharmaceuticals (UK) | inhibitors of retinoic acid–related orphan nuclear receptor gamma (ROR gamma) | development |
Autoimmune diseases | Development agreement | |
| 2015-02-25 | Avexis (USA - IL) | establishment of a new subsidiary in the EU |
Rare diseases - Genetic diseases - Neurological diseases | Establishment of a new subsidiary in the EU | ||
| 2015-02-24 | Qiagen (The Netherlands) Allele Frequency Community | collaboration |
Technology - Services | Collaboration agreement | ||
| 2015-02-24 | Biomed X (Germany) Roche (Switzerland) | collaboration R&D |
Technology - Services | Collaboration agreement |
